Coeptis Therapeutics (NASDAQ:ZSQR) Releases Quarterly Earnings Results

Coeptis Therapeutics (NASDAQ:ZSQR) posted its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, Zacks reports. Coeptis Therapeutics had a negative net margin of 773.72% and a negative return on equity of 152.53%.

Coeptis Therapeutics Price Performance

ZSQR stock traded down $0.22 during midday trading on Friday, reaching $3.94. The company had a trading volume of 248,921 shares, compared to its average volume of 405,397. The company has a market capitalization of $202.63 million, a price-to-earnings ratio of -2.42 and a beta of -0.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.25 and a quick ratio of 3.25. Coeptis Therapeutics has a 1-year low of $3.77 and a 1-year high of $21.41. The stock has a 50 day moving average price of $8.30 and a 200-day moving average price of $10.74.

Hedge Funds Weigh In On Coeptis Therapeutics

Institutional investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC boosted its holdings in shares of Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after acquiring an additional 2,500 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after purchasing an additional 4,721 shares during the last quarter. State Street Corp increased its position in shares of Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares during the period. Finally, Marshall Wace LLP bought a new position in Coeptis Therapeutics during the fourth quarter worth $259,000. Institutional investors and hedge funds own 13.88% of the company’s stock.

Analyst Ratings Changes

Separately, Wall Street Zen cut Coeptis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.